Next Generation Sequencing is a Reliable Tool for Detecting BRCA1/2 Mutations, Including Large Genomic Rearrangements

Area of Science:

• Genomics
• Molecular Diagnostics
• Cancer Genetics

Background:

• Next-generation sequencing (NGS) is a rapid and cost-effective strategy for BRCA1/2 testing.
• The Oncomine™ BRCA Research Assay utilizes NGS for simultaneous detection of small-scale mutations and large genomic rearrangements (LGRs).
• Evaluation focused on the performance of this NGS assay across different versions of Ion Reporter™ (IR) software.

Purpose of the Study:

• To evaluate the efficacy of the Oncomine™ BRCA Research Assay for comprehensive BRCA1/2 gene analysis.
• To compare the performance of NGS with traditional methods like Sanger sequencing and MLPA.
• To assess the impact of different Ion Reporter™ software versions on assay sensitivity and specificity for LGR detection.

Main Methods:

• A cohort of 258 patients with relevant cancer types or family history was studied.
• The NGS assay was applied to all patient samples.
• Results were cross-validated against Sanger sequencing for small-scale variations and MLPA for LGRs.

Main Results:

• The NGS assay successfully identified all small-scale variations detected by Sanger sequencing.
• For LGR detection, the assay demonstrated 100% sensitivity starting with IR v5.10.
• The latest software version, IR v5.16, exhibited the highest sensitivity and specificity for LGR detection.

Conclusions:

• NGS, when coupled with an updated workflow, provides a reliable method for comprehensive BRCA1/2 gene testing.
• The assay effectively screens for LGRs, aiding in efficient and accurate clinical decision-making.
• This validated NGS approach enhances the accuracy of genetic testing for hereditary cancer syndromes.